TY - JOUR
T1 - The Radiobiology of Radiopharmaceuticals
AU - Morris, Zachary S.
AU - Wang, Andrew Z.
AU - Knox, Susan J.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/1
Y1 - 2021/1
N2 - Radiopharmaceutical therapy or targeted radionuclide therapy (TRT) is a well-established class of cancer therapeutics that includes a growing number of FDA-approved drugs and a promising pipeline of experimental therapeutics. Radiobiology is fundamental to a mechanistic understanding of the therapeutic capacity of these agents and their potential toxicities. However, the field of radiobiology has historically focused on external beam radiation. Critical differences exist between TRT and external beam radiotherapy with respect to dosimetry, dose rate, linear energy transfer, duration of treatment delivery, fractionation, range, and target volume. These distinctions simultaneously make it difficult to extrapolate from the radiobiology of external beam radiation to that of TRT and pose considerable challenges for preclinical and clinical studies investigating TRT. Here, we discuss these challenges and explore the current understanding of the radiobiology of radiopharmaceuticals.
AB - Radiopharmaceutical therapy or targeted radionuclide therapy (TRT) is a well-established class of cancer therapeutics that includes a growing number of FDA-approved drugs and a promising pipeline of experimental therapeutics. Radiobiology is fundamental to a mechanistic understanding of the therapeutic capacity of these agents and their potential toxicities. However, the field of radiobiology has historically focused on external beam radiation. Critical differences exist between TRT and external beam radiotherapy with respect to dosimetry, dose rate, linear energy transfer, duration of treatment delivery, fractionation, range, and target volume. These distinctions simultaneously make it difficult to extrapolate from the radiobiology of external beam radiation to that of TRT and pose considerable challenges for preclinical and clinical studies investigating TRT. Here, we discuss these challenges and explore the current understanding of the radiobiology of radiopharmaceuticals.
UR - http://www.scopus.com/inward/record.url?scp=85089375535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089375535&partnerID=8YFLogxK
U2 - 10.1016/j.semradonc.2020.07.002
DO - 10.1016/j.semradonc.2020.07.002
M3 - Review article
C2 - 33246632
AN - SCOPUS:85089375535
SN - 1053-4296
VL - 31
SP - 20
EP - 27
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
IS - 1
ER -